Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial

Trial Profile

Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs Abatacept (Primary) ; Ciclosporin; Methotrexate; Tacrolimus
  • Indications Graft-versus-host disease; Transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Dec 2017 According to a Seattle Children's Hospital media release, the second cohort of 140 patients with human leukocyte antigen-matched unrelated donor transplants completed enrollment in November 2017, with data expected from this randomized double-blind arm of the study in the next six months.
    • 09 Dec 2017 Results presented in a Seattle Children's Hospital media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top